- $945.25m
- $1.20bn
- $310.46m
- 87
- 85
- 87
- 98
Annual income statement for Innoviva, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 261 | 337 | 392 | 331 | 310 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 318 | 268 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.7 | 15.7 | 16.8 | -122 | 197 |
| Operating Profit | 246 | 321 | 375 | 453 | 114 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 233 | 354 | 445 | 287 | 194 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 191 | 294 | 369 | 220 | 180 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 157 | 224 | 266 | 214 | 180 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 157 | 229 | 271 | 216 | 180 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.39 | 2.02 | 2.87 | 0.289 | 2.07 |